Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy

Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy

Background: Sodium glucose cotransporter 2 (SGLT2) inhibitors originally developed for the treatment of type 2 diabetes are clinically very effective drugs halting chronic kidney disease progression. The underlying mechanisms are, however, not fully understood. Methods: We generated single-cell tran...

Full description

Bibliographic Details
Main Authors: Yong-Ping Lu, Hong-Wei Wu, Ting Zhu, Xi-Tong Li, Jiao Zuo, Ahmed A. Hasan, Christoph Reichetzeder, Denis Delic, Benito Yard, Thomas Klein, Bernhard K. Krämer, Ze-Yu Zhang, Xiao-Hua Wang, Liang-Hong Yin, Yong Dai, Zhi-Hua Zheng, Berthold Hocher
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Non-diabetic kidney disease
SGLT2 inhibitor
Macrophage-myofibroblast transition
Fibrosis
Polarization
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222013361

Internet

http://www.sciencedirect.com/science/article/pii/S0753332222013361

Similar Items